Table 4.
Logistic regression analysis of the demographic and clinical factors of relapsing–remitting multiple sclerosis patients associated with sub-optimal versus optimal response to disease-modifying therapies
| Demographic and clinical factors | Univariate analysis | ||
|---|---|---|---|
| n | OR (95% CI) | P value | |
| Therapy | 1,131 | ||
| IFNβ-1a IM | Reference | – | |
| IFNβ-1b SC | 1.07 (0.74, 1.55) | 0.71 | |
| IFNβ-1a 22 μg SC | 0.82 (0.51, 1.33) | 0.42 | |
| IFNβ-1a 44 μg SC | 1.68 (1.10, 2.57) | 0.02 | |
| GA | 0.91 (0.59, 1.42) | 0.69 | |
| EDSS at baseline | 1,131 | 1.17 (1.09, 1.25) | <0.001 |
| Age | 1,131 | 0.99 (0.98, 1.00) | 0.15 |
| Age at beginning of therapy | 1,129a | 0.99 (0.98, 1.01) | 0.26 |
| Logarithm of therapy duration (years) | 1,129a | 0.84 (0.69, 1.02) | 0.08 |
| Female (vs. male) | 1,131 | 0.92 (0.69, 1.23) | 0.55 |
| Log of disease duration | 1,131 | 1.11 (0.93, 1.32) | 0.25 |
CI Confidence interval, EDSS Expanded Disability Status Scale, GA glatiramer acetate, IFN interferon, IM intramuscular, OR odds ratio, SC subcutaneous
aTwo patients had no information on the date they began therapy